Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MYGN Myriad Genetics	$6.02 +3.3%	$5.13	$3.76 ▼ $29.30	$560.10M	1.89	1.74 million shs	1.01 million shs
NLNK NewLink Genetics		$9.07	$0.82 ▼ $3.60	$162.00M	1.17	547,540 shs	N/A
RIGL Rigel Pharmaceuticals	$41.50 -1.2%	$23.69	$12.00 ▼ $43.72	$744.51M	1.21	299,903 shs	895,255 shs
VSTM Verastem	$9.08 +5.2%	$5.72	$2.34 ▼ $9.40	$558.78M	0.83	1.82 million shs	4.82 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MYGN Myriad Genetics	+5.42%	-1.02%	+27.02%	+49.10%	-79.13%
NLNK NewLink Genetics	0.00%	0.00%	0.00%	0.00%	+42.30%
RIGL Rigel Pharmaceuticals	+1.52%	+10.82%	+109.32%	+121.58%	+235.38%
VSTM Verastem	+3.73%	+11.64%	+63.76%	+3.85%	+245.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MYGN Myriad Genetics	3.6295 of 5 stars	3.1	2.0	0.0	4.1	2.3	1.7	0.0
NLNK NewLink Genetics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	1.7265 of 5 stars	1.2	1.0	0.0	0.0	2.5	1.7	3.1
VSTM Verastem	3.3221 of 5 stars	3.4	3.0	0.0	0.0	3.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MYGN Myriad Genetics	2.21	Hold	$12.45	106.89% Upside
NLNK NewLink Genetics	0.00	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	-7.95% Downside
VSTM Verastem	2.89	Moderate Buy	$13.29	46.32% Upside

Current Analyst Ratings Breakdown

Latest NLNK, RIGL, MYGN, and VSTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	VSTM Verastem	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$12.00 ➝ $13.00
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00
6/25/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$16.00 ➝ $12.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MYGN Myriad Genetics	$837.60M	0.67	$1.09 per share	5.53	$4.17 per share	1.44
NLNK NewLink Genetics	$940K	0.00	N/A	N/A	$2.11 per share	0.00
RIGL Rigel Pharmaceuticals	$179.28M	4.15	$1.08 per share	38.34	$4.57 per share	9.08
VSTM Verastem	$10K	55,878.32	N/A	N/A	$0.59 per share	15.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MYGN Myriad Genetics	-$127.30M	-$4.28	N/A	N/A	N/A	-47.45%	-5.17%	-3.44%	11/6/2025 (Estimated)
NLNK NewLink Genetics	-$42.99M	-$1.03	N/A	N/A	N/A	-4,592.84%	-41.50%	-33.95%	N/A
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	7.67	39.52	N/A	36.51%	438.89%	57.03%	11/6/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.28	N/A	N/A	N/A	N/A	-2,003.62%	-119.85%	11/5/2025 (Estimated)

Latest NLNK, RIGL, MYGN, and VSTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	VSTM Verastem	-$0.64	-$0.39	+$0.25	-$0.39	$6.01 million	$2.14 million
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
NLNK NewLink Genetics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MYGN Myriad Genetics	N/A	1.42	1.28
NLNK NewLink Genetics	N/A	7.98	7.98
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90
VSTM Verastem	2.06	3.46	3.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MYGN Myriad Genetics	99.02%
NLNK NewLink Genetics	32.32%
RIGL Rigel Pharmaceuticals	66.23%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
MYGN Myriad Genetics	2.40%
NLNK NewLink Genetics	12.70%
RIGL Rigel Pharmaceuticals	9.48%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MYGN Myriad Genetics	2,700	93.04 million	90.81 million	Optionable
NLNK NewLink Genetics	55	37.33 million	N/A	Not Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.24 million	Optionable
VSTM Verastem	50	61.54 million	60.25 million	Optionable

NLNK, RIGL, MYGN, and VSTM Headlines

Recent News About These Companies

Balyasny Asset Management L.P. Increases Stake in Verastem Inc

August 20 at 9:11 PM | gurufocus.com

Brokerages Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $13.29

August 20 at 2:11 AM | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Analysts

August 18, 2025 | marketbeat.com

Zacks Research Upgrades Verastem (NASDAQ:VSTM) to "Hold"

August 17, 2025 | marketbeat.com

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

August 17, 2025 | insidermonkey.com

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

August 17, 2025 | finance.yahoo.com

Verastem price target lowered to $14 from $16 at Mizuho

August 15, 2025 | msn.com

Verastem stock soars after KRAS inhibitor shows strong lung cancer results

August 14, 2025 | za.investing.com

Verastem Unveils Promising VS-7375 Study Results

August 14, 2025 | msn.com

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

August 13, 2025 | businesswire.com

Verastem Inc. Earnings Call: Positive Outlook with Key Achievements

August 13, 2025 | msn.com

Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

Wall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"

August 11, 2025 | marketbeat.com

Verastem (NASDAQ:VSTM) Releases Quarterly Earnings Results

August 10, 2025 | marketbeat.com

Verastem (NASDAQ:VSTM) Price Target Raised to $13.00

August 10, 2025 | marketbeat.com

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Verastem, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 8, 2025 | seekingalpha.com

Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline

August 8, 2025 | msn.com

RBC Capital Raises Verastem (VSTM) Price Target to $13. ...

August 8, 2025 | gurufocus.com

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

August 8, 2025 | finance.yahoo.com

Verastem’s Promising Market Expansion and Financial Health Drive Buy Rating

August 8, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLNK, RIGL, MYGN, and VSTM Company Descriptions

Myriad Genetics NASDAQ:MYGN

$6.02 +0.19 (+3.26%)

Closing price 04:00 PM Eastern

Extended Trading

$6.00 -0.02 (-0.33%)

As of 05:40 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

NewLink Genetics NASDAQ:NLNK

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Rigel Pharmaceuticals NASDAQ:RIGL

$41.50 -0.49 (-1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$41.38 -0.13 (-0.30%)

As of 07:16 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Verastem NASDAQ:VSTM

$9.08 +0.45 (+5.21%)

Closing price 04:00 PM Eastern

Extended Trading

$9.12 +0.04 (+0.50%)

As of 06:38 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time